Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

BIOTRONIK Conduction System Pacing With the Solia Lead - Solia CSP S

NCT: NCT06540079 · COMPLETED

NCT IDNCT06540079
StatusCOMPLETED
Start Date2024-12-18
Completion2026-06-17
SponsorBiotronik, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

The purpose of the BIO-CONDUCT study is to demonstrate the safety and effectiveness of the BIOTRONIK Solia CSP S pacing lead when implanted in the left bundle branch area (LBBA). Safety will be assessed by evaluating serious adverse device effects that occur through 3 months post-implant. Efficacy will be assessed by evaluating implant success rate.

Frequently Asked Questions

What is BIOTRONIK Conduction System Pacing With the Solia Lead - Solia CSP S?

BIOTRONIK Conduction System Pacing With the Solia Lead - Solia CSP S is a clinical trial registered under NCT06540079. Current status: COMPLETED.

What is the status of NCT06540079?

The current status of NCT06540079 (BIOTRONIK Conduction System Pacing With the Solia Lead - Solia CSP S) is: COMPLETED.

When did BIOTRONIK Conduction System Pacing With the Solia Lead - Solia CSP S start?

BIOTRONIK Conduction System Pacing With the Solia Lead - Solia CSP S started on 2024-12-18.

Related Devices

K152995BioMonitor 2-AF, BioMonitor 2-SBiotronik, Inc. K160985Pantera ProBiotronik, Inc. K163660Pantera LEOBiotronik, Inc. K170628BioMonitor 2-AF, BioMonitor 2-SBiotronik, Inc. K171514BioMonitor 2-AF, BioMonitor 2-S, FIT - Fast Insert Tool 1 + 2, SetBiotronik, Inc.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑